Thank you for your interest in volunteering for one of the University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI) coordinated studies.
To participate, please find a trial that is right for you (or someone you love) and contact a clinical site near you. Each of our studies have different eligibility criteria. While not everyone can join a trial, you can always become an advocate by sharing the trials with someone you know who might be able to participate.
To watch an informational video about why your participation in clinical trials is so important, click here.
We appreciate your support as we seek to prevent and treat Alzheimer’s disease.
Active Studies – Recruiting
The LEADS study – or the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s disease. Better understanding of this form of the disease may ultimately lead to more effective treatments. LEADS is a 2-year observational study designed to enroll 500 participants. Researchers are also recruiting cognitively normal volunteers for a 1-year comparison.
The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI). We are looking for healthy, non-smoking adults, age 55+.
Active Studies – Not Recruiting
For more information, click here.
“We call the condition of memory impairment alone amnestic Mild Cognitive Impairment (aMCI),” says Dr. Ronald Petersen, director of the NIA-funded Mayo Alzheimer’s Disease Research Center. “Researchers are particularly interested in the brain changes and memory loss of aMCI, because more people with this condition go on to develop AD than do people without it. We don’t yet know for sure whether aMCI is a separate condition or a transitional stage between normal aging and AD.”
The Early Trial
Elevations of liver enzymes, which were serious in nature, were observed in some study participants who received the Janssen BACE inhibitor, atabecestat. After a thorough evaluation of all available liver safety data from their studies, Janssen concluded that the benefit-risk ratio was no longer favorable to continue development of atabecestat for people who have late-onset preclinical stage Alzheimer’s disease.